---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-037605"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2026-08-13T12:40:15+00:00"
generated_at: "2026-08-13T12:45:14.442777+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cingulate Q2 net loss $5.9M, cash $28.4M; CTx-1301 NDA resubmission progress, Prasco deal

## Summary
- Cash and cash equivalents $28.4M as of June 30, 2026, up from $11.0M at Dec 31, 2025; runway into mid-2027.
- Q2 net loss $5.9M vs $5.0M YoY; six-month net loss $15.2M vs $8.8M; SG&A up 101.5% to $3.9M.
- FDA CRL on June 1, 2026 for CTx-1301 NDA requested additional CMC info; no safety/efficacy concerns; resubmission planned.
- U.S. Patent No. 12,653,791 issued June 16, 2026 covering CTx-1301, expires Dec 2042.
- Signed exclusive distribution agreement with Prasco, LLC on July 21, 2026 for CTx-1301 launch.

## SEC filing metadata
- accession: 0001493152-26-037605
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2026-08-13T12:40:15+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000149315226037605/0001493152-26-037605-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000149315226037605/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-037605
- JSON: https://secwatch.observer/filing/0001493152-26-037605.json
- Plain text: https://secwatch.observer/filing/0001493152-26-037605.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.